Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNXNYSE:ENOVNASDAQ:NVCRNYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$13.52-4.4%$15.43$8.89▼$24.50$586.23MN/A471,013 shs121,291 shsENOVEnovis$33.65+0.6%$32.99$28.83▼$49.83$1.92B1.7890,833 shs775,291 shsNVCRNovoCure$17.71-1.0%$17.70$14.17▼$34.13$1.97B0.721.13 million shs534,101 shsWRBYWarby Parker$22.25+1.3%$19.96$12.46▼$28.68$2.33B2.091.98 million shs564,025 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics0.00%-10.29%-29.14%+29.50%+1,351,999,900.00%ENOVEnovis0.00%+5.89%+5.85%+3.83%-24.96%NVCRNovoCure0.00%-1.64%+4.15%+6.59%+5.51%WRBYWarby Parker0.00%+1.64%+2.98%+44.20%+41.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBNXBeta BionicsN/AN/AN/AN/AN/AN/AN/AN/AENOVEnovis3.5842 of 5 stars3.43.00.00.03.21.71.9NVCRNovoCure3.6096 of 5 stars3.31.00.04.52.01.70.0WRBYWarby Parker2.1868 of 5 stars2.33.00.00.02.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.75Moderate Buy$23.4473.41% UpsideENOVEnovis 2.80Moderate Buy$58.0072.36% UpsideNVCRNovoCure 2.67Moderate Buy$32.8385.45% UpsideWRBYWarby Parker 2.61Moderate Buy$22.882.81% UpsideCurrent Analyst Ratings BreakdownLatest BBNX, WRBY, NVCR, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.006/16/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.006/12/2025BBNXBeta BionicsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$30.005/30/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$16.005/30/2025BBNXBeta BionicsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.005/29/2025WRBYWarby ParkerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $25.005/22/2025WRBYWarby ParkerRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.005/21/2025WRBYWarby ParkerCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$17.00 ➝ $22.005/21/2025WRBYWarby ParkerStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$18.00 ➝ $21.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$65.12M9.00N/AN/A($5.72) per share-2.36ENOVEnovis$2.11B0.91$19.23 per share1.75$45.10 per share0.75NVCRNovoCure$605.22M3.26N/AN/A$3.33 per share5.32WRBYWarby Parker$771.32M3.01$0.34 per share65.51$3.35 per share6.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/AENOVEnovis-$825.49M-$13.95N/A10.55N/A-37.65%5.99%3.44%8/6/2025 (Estimated)NVCRNovoCure-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)WRBYWarby Parker-$20.39M-$0.12N/A222.50N/A-1.79%-2.48%-1.29%8/6/2025 (Estimated)Latest BBNX, WRBY, NVCR, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/24/2025Q2 2025NVCRNovoCure-$0.40N/AN/AN/A$153.87 millionN/A5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/6/2025Q1 2025BBNXBeta Bionics-$0.51-$0.52-$0.01-$0.93N/AN/A4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/A15.8814.93ENOVEnovis0.522.551.32NVCRNovoCure0.271.471.41WRBYWarby ParkerN/A2.702.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/AENOVEnovis98.45%NVCRNovoCure84.61%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/AENOVEnovis2.70%NVCRNovoCure5.52%WRBYWarby Parker18.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.36 millionN/AN/AENOVEnovis7,36757.12 million55.58 millionOptionableNVCRNovoCure1,488111.49 million105.33 millionOptionableWRBYWarby Parker3,780104.50 million85.44 millionOptionableBBNX, WRBY, NVCR, and ENOV HeadlinesRecent News About These CompaniesWarby Parker Inc. (NYSE:WRBY) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 6 at 3:09 AM | americanbankingnews.comWarby Parker Inc. (NYSE:WRBY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 6 at 3:07 AM | marketbeat.com11,751 Shares in Warby Parker Inc. (NYSE:WRBY) Acquired by Diversified Trust CoJuly 2, 2025 | marketbeat.comWhat Makes Warby Parker (WRBY) an Attractive Investment?June 30, 2025 | finance.yahoo.comBessemer Group Inc. Has $1.17 Million Stock Position in Warby Parker Inc. (NYSE:WRBY)June 30, 2025 | marketbeat.comWRBY - Warby Parker Inc Ordinary Shares - Class A Chart - MorningstarJune 28, 2025 | morningstar.comMThe 5 Most Interesting Analyst Questions From Warby Parker’s Q1 Earnings CallJune 27, 2025 | msn.comWarby Parker (NYSE:WRBY) Stock Price Down 3.7% - Here's What HappenedJune 26, 2025 | marketbeat.comSG Americas Securities LLC Buys Shares of 33,023 Warby Parker Inc. (NYSE:WRBY)June 22, 2025 | marketbeat.comWarby Parker (WRBY): Buy, Sell, or Hold Post Q1 Earnings?June 20, 2025 | msn.comRiverwater Partners LLC Invests $460,000 in Warby Parker Inc. (NYSE:WRBY)June 20, 2025 | marketbeat.comVaughan Nelson Investment Management L.P. Trims Stake in Warby Parker Inc. (NYSE:WRBY)June 15, 2025 | marketbeat.comTech Giants Partner With Retailers As Smart Glasses Battle Heats UpJune 12, 2025 | forbes.comWarby Parker eyes space at trendy Raleigh shopping centerJune 11, 2025 | bizjournals.comWarby Parker Inc. (NYSE:WRBY) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 11, 2025 | marketbeat.comWRBY Q1 Earnings Call: Management Details Tariff Mitigation, Store Expansion, and Pricing ActionsJune 10, 2025 | msn.comNBC Securities Inc. Buys 11,574 Shares of Warby Parker Inc. (NYSE:WRBY)June 9, 2025 | marketbeat.comWarby Parker Co-CEO: Google AI Glasses Coming After 2025June 4, 2025 | pymnts.comWarby Parker Announces Participation in the Baird Global Consumer, Technology & Services ConferenceJune 2, 2025 | finance.yahoo.comJune 2, 2025 | gurufocus.comGoogle Is Back to Smart Glasses: This Time It Might WorkMay 28, 2025 | techopedia.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBBNX, WRBY, NVCR, and ENOV Company DescriptionsBeta Bionics NASDAQ:BBNX$13.52 -0.62 (-4.38%) As of 07/3/2025 01:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Enovis NYSE:ENOV$33.65 +0.19 (+0.57%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$33.66 +0.02 (+0.04%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.NovoCure NASDAQ:NVCR$17.70 -0.18 (-0.98%) As of 07/3/2025 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Warby Parker NYSE:WRBY$22.25 +0.29 (+1.32%) As of 07/3/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
